[
  {
    "ts": null,
    "headline": "Merck (MRK) Revises 2025 Sales Guidance and Reports Lower Q2 Earnings",
    "summary": "Merck (MRK) recently revised its 2025 sales guidance to a range of $64.3 billion to $65.3 billion, acknowledging a slight foreign exchange impact, while also announcing lower year-over-year earnings for the second quarter. Despite these developments, the company's share price moved 4% higher over the past month. This increase aligns with a stable broader market, which saw the S&P 500 maintaining gains. During the same period, Merck's dividend declaration and product approval in Canada might...",
    "url": "https://finnhub.io/api/news?id=4952134fab6c62f280261538ea43681b128f08e00b4e7a57417b215815a84c7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753897191,
      "headline": "Merck (MRK) Revises 2025 Sales Guidance and Reports Lower Q2 Earnings",
      "id": 136148953,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) recently revised its 2025 sales guidance to a range of $64.3 billion to $65.3 billion, acknowledging a slight foreign exchange impact, while also announcing lower year-over-year earnings for the second quarter. Despite these developments, the company's share price moved 4% higher over the past month. This increase aligns with a stable broader market, which saw the S&P 500 maintaining gains. During the same period, Merck's dividend declaration and product approval in Canada might...",
      "url": "https://finnhub.io/api/news?id=4952134fab6c62f280261538ea43681b128f08e00b4e7a57417b215815a84c7e"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=dc2e8d04f7fe586499b53a55ab38f2b32900f1ef4eeba7a5bd90b8370591aa2a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753893240,
      "headline": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
      "id": 136168499,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=dc2e8d04f7fe586499b53a55ab38f2b32900f1ef4eeba7a5bd90b8370591aa2a"
    }
  },
  {
    "ts": null,
    "headline": "Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?",
    "summary": "MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.",
    "url": "https://finnhub.io/api/news?id=2bc4083672fe6b991f283c1307983699316e8018a6c4de9a1dfd83c88fb4f805",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753879620,
      "headline": "Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?",
      "id": 136148954,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.",
      "url": "https://finnhub.io/api/news?id=2bc4083672fe6b991f283c1307983699316e8018a6c4de9a1dfd83c88fb4f805"
    }
  },
  {
    "ts": null,
    "headline": "Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?",
    "summary": "Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets.",
    "url": "https://finnhub.io/api/news?id=ca1101480cb2f070faa08eb7064810975d4ead41b9b7139a8246b8a03fde5129",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753878840,
      "headline": "Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?",
      "id": 136129848,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets.",
      "url": "https://finnhub.io/api/news?id=ca1101480cb2f070faa08eb7064810975d4ead41b9b7139a8246b8a03fde5129"
    }
  },
  {
    "ts": null,
    "headline": "AI Stock With Unique Focus Joins Palantir, Nvidia On 3 Elite Lists",
    "summary": "As top funds bet big on AI stocks Nvidia and Palantir, they also scooped up Veeva stock as it teases a breakout.",
    "url": "https://finnhub.io/api/news?id=f3ab8cb00f33ef30e75ec256c1058740e10c1717b100e62c1d7b939b884fca4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753876801,
      "headline": "AI Stock With Unique Focus Joins Palantir, Nvidia On 3 Elite Lists",
      "id": 136129465,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "As top funds bet big on AI stocks Nvidia and Palantir, they also scooped up Veeva stock as it teases a breakout.",
      "url": "https://finnhub.io/api/news?id=f3ab8cb00f33ef30e75ec256c1058740e10c1717b100e62c1d7b939b884fca4d"
    }
  },
  {
    "ts": null,
    "headline": "LiFT Biosciences bags €12m grant to advance novel cell therapy to clinical trials",
    "summary": "This funding will allow LiFT to take its immuno-modulatory alpha neutrophil (IMAN)-based therapy to Phase I clinical trials for solid tumour indications.",
    "url": "https://finnhub.io/api/news?id=fabf81906ce6d2fdec6f0e3af5c2533d6fb90d27c2fa628aac232f87da888092",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753874738,
      "headline": "LiFT Biosciences bags €12m grant to advance novel cell therapy to clinical trials",
      "id": 136151859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "This funding will allow LiFT to take its immuno-modulatory alpha neutrophil (IMAN)-based therapy to Phase I clinical trials for solid tumour indications.",
      "url": "https://finnhub.io/api/news?id=fabf81906ce6d2fdec6f0e3af5c2533d6fb90d27c2fa628aac232f87da888092"
    }
  },
  {
    "ts": null,
    "headline": "Infectious Disease Treatment Market Report 2025-2030 | Long-acting Injectables, Self-testing Kits, and Combination Therapies Fueling Growth",
    "summary": "The global infectious disease treatment market is projected to grow from $72.5 billion in 2025 to $101 billion by 2030, with a CAGR of 6.9%. Driven by ongoing health challenges, emerging trends include long-acting injectables, self-testing kits, and combination therapies. Key players include Gilead Sciences, Sanofi, and Merck. Infectious Disease Treatments Market Infectious Disease Treatments Market Dublin, July 30, 2025 (GLOBE NEWSWIRE) -- The \"Global Markets for Infectious Disease Treatments\"",
    "url": "https://finnhub.io/api/news?id=39425dd56c72d8a96acfc44ac6bd529fbf25e19bdaeb862305635d78cbbe6669",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753872780,
      "headline": "Infectious Disease Treatment Market Report 2025-2030 | Long-acting Injectables, Self-testing Kits, and Combination Therapies Fueling Growth",
      "id": 136129850,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global infectious disease treatment market is projected to grow from $72.5 billion in 2025 to $101 billion by 2030, with a CAGR of 6.9%. Driven by ongoing health challenges, emerging trends include long-acting injectables, self-testing kits, and combination therapies. Key players include Gilead Sciences, Sanofi, and Merck. Infectious Disease Treatments Market Infectious Disease Treatments Market Dublin, July 30, 2025 (GLOBE NEWSWIRE) -- The \"Global Markets for Infectious Disease Treatments\"",
      "url": "https://finnhub.io/api/news?id=39425dd56c72d8a96acfc44ac6bd529fbf25e19bdaeb862305635d78cbbe6669"
    }
  },
  {
    "ts": null,
    "headline": "Australia Anti-Venom Market Analysis Report 2025-2033 Featuring BSV, Boehringer Ingelheim, Boston Scientific, CSL, Merck, Pfizer, Haffkine Bio-Pharmaceutical",
    "summary": "The Australia Anti Venom Market is poised for significant growth, reaching an estimated US$ 39.27 million by 2033 from US$ 22.18 million in 2024, at a CAGR of 6.55% from 2025 to 2033. This expansion is driven by increasing snake and scorpion bites, government initiatives, and industry advancements. Key market segments include Polyvalent and Monovalent Anti-Venoms, targeting snakes, scorpions, and spiders, distributed through clinics, hospitals, and surgical centers. Despite challenges like high",
    "url": "https://finnhub.io/api/news?id=f4ed99d14bce5281098df11be77d3bd129145748873c855edeee129974794200",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753866720,
      "headline": "Australia Anti-Venom Market Analysis Report 2025-2033 Featuring BSV, Boehringer Ingelheim, Boston Scientific, CSL, Merck, Pfizer, Haffkine Bio-Pharmaceutical",
      "id": 136129851,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Australia Anti Venom Market is poised for significant growth, reaching an estimated US$ 39.27 million by 2033 from US$ 22.18 million in 2024, at a CAGR of 6.55% from 2025 to 2033. This expansion is driven by increasing snake and scorpion bites, government initiatives, and industry advancements. Key market segments include Polyvalent and Monovalent Anti-Venoms, targeting snakes, scorpions, and spiders, distributed through clinics, hospitals, and surgical centers. Despite challenges like high",
      "url": "https://finnhub.io/api/news?id=f4ed99d14bce5281098df11be77d3bd129145748873c855edeee129974794200"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Lenacapavir Injection Market size & share revenue was valued at approximately USD 3.5 Billion in 2024 and is expected to reach USD 3.66 Billion in 2025 and is expected to reach around USD 5.68 Billion by 2034, at a CAGR of 5.1% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Gilead Sciences, Dr. Reddy’s",
    "url": "https://finnhub.io/api/news?id=f63c6944462f30737ec8b786376be44a7ada2fbca06ee2972a78d9db196ebed8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753864200,
      "headline": "[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 136129715,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Lenacapavir Injection Market size & share revenue was valued at approximately USD 3.5 Billion in 2024 and is expected to reach USD 3.66 Billion in 2025 and is expected to reach around USD 5.68 Billion by 2034, at a CAGR of 5.1% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Gilead Sciences, Dr. Reddy’s",
      "url": "https://finnhub.io/api/news?id=f63c6944462f30737ec8b786376be44a7ada2fbca06ee2972a78d9db196ebed8"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co Inc (MRK) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...",
    "summary": "Despite a revenue dip, Merck & Co Inc (MRK) showcases strong oncology sales, strategic acquisitions, and a promising pipeline to drive future growth.",
    "url": "https://finnhub.io/api/news?id=5ee1fcebb76d81dfe6e9b3f423efd5a3b36b6985e689bd0a42795f909b780415",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753859415,
      "headline": "Merck & Co Inc (MRK) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...",
      "id": 136129853,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Despite a revenue dip, Merck & Co Inc (MRK) showcases strong oncology sales, strategic acquisitions, and a promising pipeline to drive future growth.",
      "url": "https://finnhub.io/api/news?id=5ee1fcebb76d81dfe6e9b3f423efd5a3b36b6985e689bd0a42795f909b780415"
    }
  }
]